Initial general form for registration of a class of securities pursuant to Section 12(g)

Condensed Consolidated Balance Sheets

v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Current assets:      
Cash $ 1,040 $ 46 $ 31,294
Accounts receivable, net (including related party receivable of $16,023 and $21,852 at March 31, 2022 and December 31, 2021, respectively) 26,953 32,800 151,363
Prepaid expenses and other current assets 1,717
Total current assets 27,993 32,846 184,374
Property and equipment, net 685
Total assets 27,993 32,846 185,059
Current liabilities:      
Accounts payable 946,244 937,698 726,220
Accrued expenses 1,483,628 1,446,722 1,308,283
Due to Former Parent 501,637 374,473
Current portion of notes payable 206,157 134,153 134,118
Total current liabilities 3,137,666 2,893,046 2,168,621
Notes payable – Long term 60,401 60,401 103,900
Total liabilities 12,421,713 12,161,843 2,272,521
Stockholders’ Deficit      
Preferred Series A Stock, Par Value $0.0001, 1,000 shares authorized, 1,000 shares issued and outstanding at March 31, 2022 and December 31, 2021
Common Stock, Par Value $0.0001, 325,000,000 shares authorized, 234,953,286 shares issued and outstanding at March 31, 2022 and December 31, 2021 23,495 23,495
Additional Paid-In Capital 5,857,658 5,857,658
Accumulated Deficit (18,274,873) (18,010,150)
Parent’s net investment deficit in Advanced Molecular and Health Technology Solutions Group   (2,087,462)
Total Stockholders’ Deficit (12,393,720) (12,128,997) (2,087,462)
Total Liabilities and Stockholders’ Deficit 27,993 32,846 185,059
Series B Preferred Stock [Member]      
Current liabilities:      
Total temporary capital 9,086,396 9,086,396
Series C Preferred Stock [Member]      
Current liabilities:      
Total temporary capital 137,250 $ 122,000
Stockholders’ Deficit      
Preferred Series A Stock, Par Value $0.0001, 1,000 shares authorized, 1,000 shares issued and outstanding at March 31, 2022 and December 31, 2021 $ 15,250